PPIL2

Across TCGA pan-cancer cohorts, PPIL2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PPIL2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PPIL2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PPIL2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where PPIL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.927	0.676	<.001	60	view →
HNSC	DFS	Tertile	III,IV	0.516	0.837	.008	22	view →
LSCC	OS	Quartile	All	0.920	0.718	.018	12	view →
CCRCC	DFS	Tertile	III,IV	0.714	1.000	.008	8	view →
UCEC	DFS	Median	All	1.000	0.936	.023	6	view →
GBM	OS	Median	All	0.573	0.246	.009	5	view →
LUAD	OS	Tertile	All	0.837	0.641	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PPIL2–PDAC (DFS)

Open the PDAC breakdown →